Copy Link Print Information

Oxytocin free acid TFA

(Synonyms: 9-Deamidooxytocin TFA)
16 Cited Publications
Customer Review

Based on 16 publication(s) in Google Scholar

Oxytocin free acid (9-Deamidooxytocin) TFA is an analog of oxytocin in which the glycinamide residue at position 9 in oxytocin has been replaced by a glycine residue. Oxytocin is a pleiotropic, peptide hormone with broad implications for general health, adaptation, development, reproduction, and social behavior.

For research use only. We do not sell to patients.

  • Purity: 99.61%
  • Formula: C45H66F3N11O15S2
  • Molecular Weight:1122.20
  • Storage:

    Sealed storage, away from moisture.

    Powder   -80°C, 2 years , -20°C, 1 year

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Oxytocin free acid TFA Chemical Structure
    Oxytocin free acid TFA Chemical Structure
  • Experimental Validation Results for Oxytocin free acid TFA
  • Experimental Validation Results for Oxytocin free acid TFA
  • Experimental Validation Results for Oxytocin free acid TFA
  • Experimental Validation Results for Oxytocin free acid TFA
  • Experimental Validation Results for Oxytocin free acid TFA
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Oxytocin free acid TFA:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Oxytocin free acid TFA

More
Customer Validation & Images
IFRT-PCRWBIn Vivo Efficacy Study
  • RT-PCR
  • In Vivo Efficacy Study
  • IF
  • WB
  • In Vivo Efficacy Study
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Oxytocin free acid TFA Chemical Structure
    Oxytocin free acid TFA Chemical Structure
    1/16
  • 1/16

    Oxytocin free acid TFA purchased from MedChemExpress. Usage Cited in: Psychoneuroendocrinology. 2024 Oct:168:107138. [Abstract]

    Customer Validation
     Expression of OT (Oxytocin) signaling related genes in the hippocampus. RT-PCR analysis were performed on brain tissues from the hippocampus. Con: control; Veh: Vehicle (Saline); RIS: Risperidone; LOT: Low dose (6 μg/kg) of OT; MOT: Medium dose (20 μg/kg) of OT; HOT: High dose (60 μg/kg) of OTAfter 1 week of acclimation, animals in the control group were administered saline (10 ml/kg) and those in the model group were administered MK801 (0.6 mg/kg) through intraperitoneal (i. p.) injections once a day for 21 days. One week after MK801 administration, 6 μg/kg OT (LOT group, n = 10), 20 μg/kg OT (MOT group, n = 10), or 60 μg/kg OT (HOT group, n = 10) was given through the i.n. route twice daily, at 8:30–9:30 AM and 4:00–5:00 PM, for 14 days. Saline (0.2 μL/g) was administered intranasally in the control and vehicle groups. Then, the mice received an i.p. injection of MK801 30 min after OT administration. The mice in the RIS group received an i.p. injection of 0.3 mg/kg RIS once daily for 14 days

  • 1/16

    Oxytocin free acid TFA purchased from MedChemExpress. Usage Cited in: Psychoneuroendocrinology. 2024 Oct:168:107138. [Abstract]

    Customer Validation
     Effects of chronic intranasal OT (Oxytocin) on levels of spontaneous activity and anxiety-like behaviors in MK801-induced mice Fig. A, the total distance traveled by the mice in the open field test. Fig. 2B, the ratio of distance traveled in the central versus peripheral zone by the mice in the open field test. Con: control; Veh: Vehicle (Saline); RIS: Risperidone; LOT: Low dose (6 μg/kg) of OT; MOT: Medium dose (20 μg/kg) of OT; HOT: High dose (60 μg/kg) of OTAfter 1 week of acclimation, animals in the control group were administered saline (10 ml/kg) and those in the model group were administered MK801 (0.6 mg/kg) through intraperitoneal (i.p.) injections once a day for 21 days. One week after MK801 administration, 6 μg/kg OT (LOT group, n = 10), 20 μg/kg OT (MOT group, n =10), or 60 μg/kg OT (HOT group, n = 10) was giventhrough the i.n. route twice daily, at 8:30–9:30 AM and 4:00–5:00 PM, for 14 days. Saline (0.2 μL/g) was administered intranasally in the control and vehicle groups. Then, the mice received ani.p. injection of MK801 30 min after OT administration. The mice in the RIS group received an i.p. injection of 0.3 mg/kg RIS once daily for 14 days.

  • 1/16

    Oxytocin free acid TFA purchased from MedChemExpress. Usage Cited in: J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]

    Customer Validation
     Effect of OT on CGRP and c-fos expression levels. A and C show c-fos, B and D show CGRP. Immunofluorescence staining showed that the number of c-fos-positive cells per FOV and the average fluorescence intensity of CGRP were significantly increased in the NTG + vehicle group compared with the sham group. OT administration significantly reduced the expression of CGRP and c-fos, while these effects were prevented after adding L368,899. Repeated OT (Oxytocin, 20 µg/kg) treatments were quickly administered at 2 µL per nostril or the same volume of saline every two minutes using the tip of the pipette 30 min before NTG and then once daily at the same time point for 11 days.C57BL/6 mice weighing 20 ~ 30 g and 6 ~ 8 weeks of age.

  • 1/16

    Oxytocin free acid TFA purchased from MedChemExpress. Usage Cited in: J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]

    Customer Validation
     WB data quantification in the mouse trigeminal nucleus caudalis. Repeated OT (Oxytocin, 20 µg/kg) treatments were quickly administered at 2 µL per nostril or the same volume of saline every two minutes using the tip of the pipette 30 min before NTG and then once daily at the same time point for 11 days.C57BL/6 mice weighing 20 ~ 30 g and 6 ~ 8 weeks of age.

  • 1/16

    Oxytocin free acid TFA purchased from MedChemExpress. Usage Cited in: J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]

    Customer Validation
     OT ameliorated pain sensitization and reduced neuronal activation via OTR. Note that L-368,899 was intraperitoneally injected daily 1 h before OT treatment. The mechanical and thermal pain thresholds of the hind paw and periorbital area were assessed before each NTG injection and on day 11. B, C, D The basal mechanical pain thresholds of the hind paw (B), periorbital area (C), and the thermal pain response of the hind paw (D) were significantly increased in the NTG + OT group compared with the NTG + vehicle group.The pain threshold in the NTG + OT + L368,899 group was markedly decreased compared with the NTG + OT group.Repeated OT (Oxytocin, 20 µg/kg) treatments were quickly administered at 2 µL per nostril or the same volume of saline every two minutes using the tip of the pipette 30 min before NTG and then once daily at the same time point for 11 days.C57BL/6 mice weighing 20 ~ 30 g and 6 ~ 8 weeks of age.

  • Oxytocin free acid TFA